Zevra Therapeutics (NASDAQ:ZVRA) Shares Down 10%

Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Get Rating)’s share price fell 10% during mid-day trading on Tuesday . The company traded as low as $4.41 and last traded at $4.43. 351,489 shares traded hands during mid-day trading, an increase of 51% from the average session volume of 233,420 shares. The stock had previously closed at $4.92.

Analyst Upgrades and Downgrades

Separately, Maxim Group initiated coverage on shares of Zevra Therapeutics in a research note on Friday, March 17th. They issued a “buy” rating and a $12.00 price target on the stock.

Zevra Therapeutics Price Performance

The company has a market capitalization of $153.01 million, a P/E ratio of -3.69 and a beta of 2.21. The stock’s fifty day moving average is $5.31. The company has a quick ratio of 7.93, a current ratio of 7.93 and a debt-to-equity ratio of 0.15.

Insider Buying and Selling

In other Zevra Therapeutics news, Director Matthew R. Plooster purchased 11,000 shares of the firm’s stock in a transaction dated Thursday, March 9th. The shares were acquired at an average price of $4.20 per share, with a total value of $46,200.00. Following the purchase, the director now directly owns 18,500 shares in the company, valued at approximately $77,700. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Zevra Therapeutics news, CEO Richard W. Pascoe bought 10,000 shares of the business’s stock in a transaction dated Thursday, March 9th. The shares were acquired at an average price of $4.20 per share, with a total value of $42,000.00. Following the transaction, the chief executive officer now owns 29,973 shares of the company’s stock, valued at $125,886.60. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Matthew R. Plooster purchased 11,000 shares of the business’s stock in a transaction on Thursday, March 9th. The shares were purchased at an average cost of $4.20 per share, for a total transaction of $46,200.00. Following the transaction, the director now owns 18,500 shares of the company’s stock, valued at $77,700. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 26,444 shares of company stock worth $112,048. 1.10% of the stock is owned by corporate insiders.

About Zevra Therapeutics

(Get Rating)

Zevra Therapeutics, Inc is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy.